Court Hears Arguments in Jemperli Rights Dispute
The Delaware Court of Chancery held a post-trial hearing following an expansion of FDA approval for the cancer drug.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Do you trust that major corporate contract disputes are resolved fairly for all stakeholders involved?
The Delaware Court of Chancery held a post-trial hearing on October 20 regarding a contract dispute between AnaptysBio, GSK, and Tesaro over rights to the drug Jemperli. The legal action follows the FDA's recent expansion of approval for the treatment for a specific type of rectal cancer.
Why it matters
The dispute centers on allegations that Tesaro breached a collaboration agreement and that GSK interfered with the contract. AnaptysBio is currently seeking the return of rights to the drug it originally discovered.
The Delaware Court of Chancery held a post-trial hearing at 1:30 p.m. ET to address claims involving Jemperli. Following the session, AnaptysBio shares declined 7.74% while GSK shares increased 2.37%.
The players
AnaptysBio
This is a clinical-stage biotechnology company that focuses on the development of antibody therapeutics for inflammation and immuno-oncology.
GSK
Also known as GlaxoSmithKline, this is a British multinational pharmaceutical and biotechnology company headquartered in London.
Tesaro
This is an oncology-focused biopharmaceutical company that was acquired by GSK in 2019.
Delaware Court of Chancery
This is a non-jury trial court in Delaware that hears cases involving business and corporate law.
The details
AnaptysBio, which discovered Jemperli, claims that Tesaro violated their collaboration agreement and that GSK interfered in the deal. GSK and Tesaro continue to dispute these allegations as the case moves toward a final decision.
Timeline
The case went to trial between July 14 and July 17, 2026.
The FDA granted expanded U.S. approval for Jemperli on October 19, 2026.
The Delaware Court of Chancery held a post-trial hearing at 1:30 p.m. ET on October 20, 2026.
A final ruling in the case is expected by the fourth quarter of 2026 or the first quarter of 2027.
Health Landscape
The dispute over Jemperli rights follows the acquisition of Tesaro by GSK, illustrating how legacy collaboration agreements often lead to litigation after corporate mergers. This shift highlights the complexities of drug ownership and intellectual property rights within large-scale pharmaceutical portfolios.
The legal dispute over the rights to Jemperli does not immediately alter the availability of the drug for patients following its expanded FDA approval. Patients should consult their healthcare providers regarding treatment options and potential access to the medication.
The takeaway
This case underscores the intense focus on intellectual property within the oncology sector as drug applications expand. Companies continue to face protracted legal challenges over the ownership of high-value treatments despite regulatory success.
What happens next
A final ruling in the Jemperli rights dispute is expected to be delivered by the court between the fourth quarter of 2026 and the first quarter of 2027.
Further reading
For more information on current developments, visit the Cancer section.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you trust that major corporate contract disputes are resolved fairly for all stakeholders involved?
